---
schema_version: "secwatch.filing_event.v1"
accession: "0001698530-22-000085"
form_type: "8-K"
ticker: "XCUR"
cik: "0001698530"
company_name: "EXICURE, INC."
filed_at: "2022-11-14T23:59:59+00:00"
generated_at: "2026-06-21T20:38:58.231894+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 1.0
calibrated_materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# Exicure reports Q3 loss $5.2M; wind-down & going concern; $5.4M PIPE pending vote

## Summary
- Net loss $5.2M vs $23.5M; revenue $2.0M vs $(3.7)M due to AbbVie collaboration adjustment.
- Cash $16.8M (down from $48.3M Dec 2021); expects to fund into Q2 2023; substantial doubt about going concern; may need bankruptcy if PIPE fails.
- Private placement with CBI USA: 3.4M shares at $1.60, ~$5.4M gross; CBI to hold 50.4% after close; shareholder vote Dec 15, 2022.
- Company winding down preclinical programs, cut 66% workforce, suspended all R&D; seeking out-license for cavrotolimod and SCN9A program.

## SEC filing metadata
- accession: 0001698530-22-000085
- form_type: 8-K
- ticker: XCUR
- cik: 0001698530
- company_name: EXICURE, INC.
- filed_at: 2022-11-14T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 1.0
- calibrated_materiality_score: 1.0
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1698530/000169853022000085/0001698530-22-000085-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1698530/000169853022000085/xcur-20221114.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001698530-22-000085
- JSON: https://secwatch.observer/filing/0001698530-22-000085.json
- Plain text: https://secwatch.observer/filing/0001698530-22-000085.txt

## Key facts
- Earnings Releases
  EXICURE, INC. reported quarter ended September 30, 2022 results: revenue $2.0 million, net income $5.2 million.
  - Period: quarter ended September 30, 2022
  - Revenue: $2.0 million
  - Net income: $5.2 million
  - Result: reported results
  source text: proceeds from the Private Placement as the Private Placement has not closed) will enable it to fund its current operations into the second quarter of 2023. Revenue : Revenue was $2.0 million for the quarter ended September 30, 2022, reflecting an increase of $5.7 million from revenue of $(3.7) million for the quarter ended September 30, 2021. The increase in
  evidence_url: https://www.sec.gov/Archives/edgar/data/1698530/000169853022000085/0001698530-22-000085-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.